At Bioptigen, we have lead the industry with high resolution image quality and system versatility. We were the first company to introduce OCT systems convertible from posterior to anterior imaging, the first company to introduce OCT imaging for neonates and premature infants, and the first to introduce handheld OCT perioperative applications. Our mission today is to bring our fundamental capabilities to the broader pediatric and perioperative markets, improve our ease of use, and introduce new tools for research and clinical diagnostics. We will constantly strive to be your preferred partner in research and opening new avenues of diagnostic ocular healthcare.

from http://www.bioptigen.com/

Research Grants 21 show all


$2.7M
2011

$1.4M
2012

$448.5K
2014

$955.1K
2015

$543K
2016

Patents 146show all

  • 95
    A61B - Diagnosis
  • 72
    G01B - Measuring length, thickness or similar linear dimensions
  • 41
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 16
    G02B - Optical elements, systems, or apparatus
  • 14
    G06T - Image data processing or generation, in general
  • 7
    G01J - Measurement of intensity, velocity, spectral content, polarisation, phase or pulse characteristics of infra-red, visible or ultra-violet light
  • 6
    G06K - Recognition of data
  • 5
    A63F - Card, board, or roulette games
  • 5
    G01P - Measuring linear or angular speed, acceleration, deceleration, or shock
  • 4
    H04L - Transmission of digital information, e.g. telegraphic communication

SEC Filings show all


2
D

Contact Information

Morrisville, NC
United States

SEC Form D Funding Events

DateOfferedSoldType
2011-03-03$1,500,000$1,500,000Equity
2007-09-21Unknown Unknown Other (Paper Filing)

Key Executives

  • Eric L. Buckland
    Executive Officer, Director
  • Thomas D Livingston
    Executive Officer